Please assess the completion status of the following clinical trial:

Trial Title: Can GnRH Agonist Trigger Prevent Ovarian Hyperstimulation Syndrome?

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* A female patient who needs IVF to become pregnant.~* Regular menstrual cycle.~* Antral follicular count (AFC) \> 18~* Following treatment with follitropin beta more than 18 follicles ≥ 11 mm will develop.~Exclusion Criteria:~* Hypersensitivity to the active substance or to any of the medications used.~* Tumors of the ovary, breast, uterus, pituitary or hypothalamus.~* Pregnancy.~* Abnormal (not menstrual) vaginal bleeding without a known/diagnosed cause.~* Primary ovarian failure.~* Ovarian cysts or enlarged ovaries.~* A history of Ovarian Hyperstimulation Syndrome (OHSS).~* A previous COS cycle that resulted in more than 30 follicles \> 11 mm measured by ultrasound examination.~* Fibroid tumours of the uterus incompatible with pregnancy.~* Malformations of the reproductive organs incompatible with pregnancy

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 42 Years
- Healthy Volunteers: f

Study Arms:
- OHSS high risk patients (Type: EXPERIMENTAL): Triptorelin 0.2 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).